Alexander JT, Staab EM, Wan W, Franco M, Knitter A, Skandari MR, et al
Persistent nausea and vomiting that prevents you from keeping down food or liquids for more than 24 hours, as this can lead to dehydration and electrolyte imbalances
The launch of generic liraglutide (Teva, August 2025) and anticipated oral GLP-1 options (oral Wegovy approved December 2025, orforglipron pending) offer lower-cost alternatives that may simplify pharmacy benefit management
The pharmacological action of semaglutide is highly specific
With the improved cancer management in recent years, the uptake of micronutrient supplements like vitamins and minerals complements the standard therapy in patients (37)